

# Aurobindo gets FDA final approval for autoimmune drug Tofacitin

The drug is therapeutically equivalent to Xeljanz of PF Prism C.V. and has an estimated market size of \$ 494 million for the 12-month period ending April this year, according to IQVIA.



New Delhi: Aurobindo Pharma has received a final approval from the US Food and Drug Administration (USFDA) to manufacture and market autoimmune disease therapy tofacitinib.

The drug is therapeutically equivalent to Xeljanz of PF Prism C.V. and has an estimated market size of \$ 494 million for the 12-month period ending April this year, according to IQVIA.

Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis and active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate.

The small molecule is a type of immunomodulatory medication that works by blocking JAK enzymes involved in inflammation and immune system signaling.

## News Source:

<https://pharma.economicstimes.indiatimes.com/news/drug-approvals-and-launches/aurobindo-gets-fda-final-approval-for-autoimmune-drug-tofacitin/131578902>